Rezolute
Update in progressRZLT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Rezolute, Inc. is a late-stage rare disease company focused on improving outcomes for people with hypoglycemia due to hyperinsulinism in the United States. Its lead asset, ersodetug, is an intravenously administered human monoclonal antibody in Phase 3 for congenital hyperinsulinism and related hypoglycemia, and in trials for tumor hyperinsulinism. Formerly AntriaBio, it rebranded in 2017. Founded in 2010, it is based in Redwood City, California.
Company score
- Sentiment
- -0.07
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- -0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.03
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.02
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!